Xeltis AG
http://www.xeltis.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Xeltis AG
News We’re Watching: DMCA Judicial Review Upheld; Abbott’s Rio CGM Available OTC; J&J’s Velys Wins FDA UKA Expansion
This week, AdvaMed and MITA win appeal to prevent repair companies from hacking medical devices, the FDA cleared Abbott’s Libre Rio CGM for OTC sales, J&J MedTech wins expanded clearance for Velys knee medical robot, the FDA updates its AI program, Canary Speech secures $13m in series A funding and Xeltis won FDA approval for an IDE submission to begin enrolling patients for a pivotal study for aXess.
Minute Insight: Xeltis’ Vascular Access Graft Stays Patent In First-In-Human Trial
Xeltis’ aXess graft demonstrated high patency rates and no infections after six months in the first-in-human trial.
Minute Insight: Xeltis Expects The US Trial Of 'Living' Vascular Graft To Start This Year
Xeltis hemodialysis access graft, made of its proprietary electrospun supramolecular polymer material, is advancing in clinical trials in Europe and will likely be ready for a US trial by the end of this year, according to the company.
European Investor LSP Raises $600M For Life Sciences Fund
LSP says its new fund for medical device and drug development companies will be the biggest fund dedicated to life sciences companies in Europe.
Company Information
- Industry
-
Medical Devices
- Implantable Devices
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice